UK pharma major GSK has entered an agreement to acquire 35Pharma Inc, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based ...

Ireland headquartered Alkermes (Nasdaq: ALKS) has announced that Richard Pops will retire from his role as chief executive (CEO), effective July 31, 2026.

In a major boost for India’s generics industry, the Delhi High Court has ruled that Macleods Pharmaceuticals may continue its ...

Australian biotech Neurizon (ASX: NUZ) has dosed the first participant with NUZ-001 in Regimen I of the US-based HEALEY ALS Platform Trial, launching a key Phase II/III study in amyotrophic lateral ...

ViiV Healthcare, the HIV specialist majority owned by GSK, has announced week 96 and end of study results from the Phase I/II IMPAACT 2017 study, the first trial to evaluate a complete injectable long ...

Privately-held US firm Abcuro has announced topline results from the Phase II/III MUSCLE study of ulviprubart (ABC008).

Japan’s Astellas Pharma and USA-based Vir Biotechnology have entered into a global strategic collaboration to advance VIR-5500, an investigational PRO-XTEN dual-masked CD3 T-cell engager (TCE) ...

Latin American specialty pharma company SteinCares has signed a licensing agreement with India’s Shilpa Biologicals to commercialize a biosimilar across Latin America, marking the Indian group’s first ...

Denmark’s Novo Nordisk has announced—effective January 1, 2027—a lower $675 US list price, or wholesale acquisition cost (WAC), for Wegovy (semaglutide) injection 2.4mg and tablets 25mg, Ozempic ...

US biotech Generate Biomedicines has set terms for a proposed Nasdaq listing that could raise up to $425 million, as it moves to finance two Phase III asthma trials for its lead antibody. The company ...

US pharma giant Pfizer (NYSE: PFE) has struck a commercialization deal with China’s Sciwind Biosciences for the GLP-1 drug Xianyida (ecnoglutide), gaining exclusive rights in mainland China in a pact ...

US biotech Slate Medicines has launched with $130 million in series A funding to advance an experimental migraine antibody licensed from China-based DartsBio Pharmaceuticals into the clinic next year.